SCHEMBL5158480

SCHEMBL5158480

Cc1cc(F)ccc1C1CN(C(=O)CN2CCCC2)CCC1OCc1ccccc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
CD274 Q9NZQ7 9/20 0.38
KDM4E B2RXH2 1/20 0.37
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
PDCD1 Q15116 2/20 0.36
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TACR1 P25103 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158712 0.90 MEN1 (0.39) KDM4ESIGMAR1ALDH1A1TACR1
SCHEMBL5156409 0.89 KDM4E (0.38) KDM4ECCNT1CDK9SIGMAR1ALDH1A1
SCHEMBL5158051 0.89 SIGMAR1 (0.37) KDM4ECCNT1CDK9SIGMAR1TACR1
SCHEMBL5158058 0.89 SIGMAR1 (0.37) KDM4ECCNT1CDK9SIGMAR1CARM1
SCHEMBL5177649 0.88 SIGMAR1 (0.38) KDM4ECCNT1CDK9SIGMAR1TACR1
SCHEMBL6482708 0.88 SIGMAR1 (0.41) KDM4ECCNT1CDK9SIGMAR1ALDH1A1
SCHEMBL5158362 0.88 TACR1 (0.37) KDM4ECCNT1CDK9SIGMAR1TACR1
SCHEMBL5159324 0.87 CCNT1 (0.39) KDM4ECCNT1CDK9SIGMAR1TACR1
SCHEMBL5161137 0.87 TACR1 (0.40) KDM4ECARM1PRMT6ALDH1A1MAPT
SCHEMBL5161746 0.87 CCNT1 (0.39) KDM4ECCNT1CDK9SIGMAR1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US claimed
EP-1748984-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS Pfizer Products Inc. (US) 2007-02-07 EP disclosed
WO-2005110987-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256164-A1 NK1 and NK3 antagonists TAC3, TACR1, TACR2 CHRNB2 793/4885CHRNB4 531/4885CHRNA3 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.